Phase I Study Of CC-90011 In Patients With Advanced Solid Tumors ...
ESMOMeeting CalendarOncologyPRODaily ReporterLoginNo results foundSearchLegal
- Terms of Use
- Privacy Policy
- Change cookie settings
Useful links
- About OncologyPRO
- Sponsors
- Contact us
Subscribe to ESMO newsletter
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH © Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.Từ khóa » Cc-90011
-
Discovery Of CC-90011: A Potent And Selective Reversible Inhibitor ...
-
Discovery Of CC-90011: A Potent And Selective ... - PubMed
-
A Safety And Efficacy Study Of CC-90011 In Combination With ...
-
Phase I Study Of CC-90011 In Patients With ... - Annals Of Oncology
-
Phase I Study Of Lysine-Specific Demethylase 1 Inhibitor, CC-90011 ...
-
Phase 1/2 Study Investigating CC-90011, A Potent, Selective, And ...
-
Pulrodemstat (CC-90011) Besylate - LSD1 Inhibitor
-
A Phase 1b Study Of CC-90011, A Potent, Reversible, Oral LSD1 ...
-
Phase I Study Of CC-90011 In Patients With Advanced Solid Tumours ...
-
Clinical Activity Of CC‐90011, An Oral, Potent, And Reversible LSD1 ...
-
LSD1/KDM1A Inhibitors In Clinical Trials: Advances And Prospects
-
CC-90011 | Ligand Page | IUPHAR/BPS Guide To PHARMACOLOGY
-
Pulrodemstat Benzenesulfonate (CC-90011 ... - MedChemExpress
-
CC-90011-ST-001 - Health Research Authority